Brief: Selecta Announces Transition Of Manufacturing And Clinical Operations Of Immtor For Sel-212 To Commercialization Partner SOBI

Cartesian Therapeutics

31/10/2023 20:22

Oct 31 (Reuters) - Selecta Biosciences Inc  SELB.O :
    * SELECTA ANNOUNCES TRANSITION OF MANUFACTURING AND CLINICAL
OPERATIONS OF IMMTOR FOR SEL-212 TO COMMERCIALIZATION PARTNER
SOBI
    * SELECTA BIOSCIENCES INC - AS OF NOVEMBER 6 SOBI WILL
ASSUME
RESPONSIBILITY FOR MANUFACTURING AND COMMERCIAL SUPPLY OF IMMTOR
FOR SEL-212

Source text for Eikon:  ID:nGNX2hSgbC 
Further company coverage:  SELB.O 

 ((Reuters.Briefs@thomsonreuters.com;))